Integra Lifesciences Holdings Profit Margin

The latest profit margin for IART is -0.44% as of June 2026. That compares with -30.87% in the prior-year period — up 98.6% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Integra Lifesciences Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, IART's profit margin moved from -30.87% to -0.44% — a 98.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Integra Lifesciences Holdings's valuation or profitability profile.

Against Healthcare companies, IART currently prints -0.44% for profit margin, while the sector average sits near 14.34%. That is roughly 103.1% below the sector mean. Large gaps often invite a closer look at Integra Lifesciences Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively Integra Lifesciences Holdings converts resources into returns. At -0.44%, IART may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -30.87% in the prior-year period — up 98.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IART's profit margin (-0.44%), review year-over-year change from -30.87%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.